CD70 has emerged as a promising solid tumor target for chimeric antigen receptor (CAR)–bearing T or natural killer (NK) cells, with one allogeneic CAR T-cell therapy, CTX130, showing preliminary efficacy in renal cell carcinoma. Further, assessments of a cord blood–derived CAR-NK alternative have started; the trial will be the first to use cryopreserved NK cells.

You do not currently have access to this content.